Inpatient signs and symptoms and factors associated with

death in children aged 5 years and younger admitted to

two Ebola management centres in Sierra Leone, 2014:

a retrospective cohort study by Shah, Tejshri et al.
Articles
www.thelancet.com/lancetgh   Vol 4   July 2016 e495
Inpatient signs and symptoms and factors associated with 
death in children aged 5 years and younger admitted to 
two Ebola management centres in Sierra Leone, 2014: 
a retrospective cohort study
Tejshri Shah, Jane Greig, Linda Margaretha van der Plas, Jay Achar, Grazia Caleo, James Sylvester Squire, Alhaji Sayui Turay, Grace Joshy, 
Catherine D’Este, Emily Banks, Florian Vogt, Kamalini Lokuge
Summary
Background Médecins Sans Frontières (MSF) opened Ebola management centres (EMCs) in Sierra Leone in Kailahun 
in June, 2014, and Bo in September, 2014. Case fatality in the west African Ebola virus disease epidemic has been 
highest in children younger than 5 years. Clinical data on outcomes can provide important evidence to guide future 
management. However, such data on children are scarce and disaggregated clinical data across all ages in this 
epidemic have focussed on symptoms reported on arrival at treatment facilities, rather than symptoms and signs 
observed during admission. We aimed to describe the clinical characteristics of children aged 5 years and younger 
admitted to the MSF EMCs in Bo and Kailahun, and any associations between these characteristics and mortality.
Methods In a retrospective cohort study, we included data from children aged 5 years and younger with laboratory-
conﬁ rmed Ebola virus disease admitted to EMCs between June and December, 2014. We described epidemiological, 
demographic, and clinical characteristics and viral load (measured using Ebola virus cycle thresholds [Ct]), and 
assessed their association with death using Cox regression modelling.
Findings We included 91 children in analysis; 52 died (57·1%). Case fatality was higher in children aged less than 
2 years (76·5% [26/34]) than those aged 2–5 years (45·6% [26/57]; adjusted HR 3·5 [95% CI 1·5–8·5]) and in those 
with high (Ct<25) versus low (Ct≥25) viral load (81·8% [18/22] vs 45·9% [28/61], respectively; adjusted HR 9·2 [95% CI 
3·8–22·5]). Symptoms observed during admission included: weakness 74·7% (68); fever 70·8% (63/89); distress 
63·7% (58); loss of appetite 60·4% (55); diarrhoea 59·3% (54); and cough 52·7% (48). At admission, 25% (19/76) of 
children were afebrile. Signs signiﬁ cantly associated with death were fever, vomiting, and diarrhoea. Hiccups, 
bleeding, and confusion were observed only in children who died.
Interpretation This description of the clinical features of Ebola virus disease over the duration of illness in children 
aged 5 years and younger shows symptoms associated with death and a high prevalence of distress, with implications 
for clinical management. Collection and analysis of age-speciﬁ c data on Ebola is very important to ensure that the 
speciﬁ c vulnerabilities of children are addressed.
Funding No speciﬁ c funding was received for this study. EB is supported by the National Health and Medical Research 
Council of Australia.
Copyright Shah et al. Open Access article distributed under the terms of CC BY.
Introduction
By Aug 16, 2015, 27 952 cases of Ebola virus disease had 
been reported in Guinea, Liberia, and Sierra Leone as 
part of the west Africa Ebola epidemic.1 Of the 
15 186 people with laboratory-conﬁ rmed infection, 20% 
were aged 14 years or younger.1 Sierra Leone had the 
highest rate and absolute number of conﬁ rmed infections 
in this age group.1
Evidence from all age groups shows that case fatality is 
highest in children under 5 years, suggesting that young 
children have diﬀ erent risks than do older children, 
adolescents, and adults.2 However, data on the 
epidemiological, clinical, and laboratory features of Ebola 
virus disease in children are scarce.3–5 Furthermore, 
clinical data across all age groups published from the 
2013–16 outbreak have captured historic symptoms 
reported on arrival to Ebola management facilities, and 
omitted ongoing signs objectively observed by clinical 
staﬀ  during admission.2,6–8 Data on signs collected during 
admission have the potential to inform clinical practice 
and to improve our understanding of Ebola virus disease.
The ﬁ rst ever case of Ebola virus disease in Sierra 
Leone was reported in May, 2014, in Kailahun, a rural 
district in the southeast of the country, adjacent to the 
Guéckédou region of Guinea where the outbreak 
originated. Médecins Sans Frontières (MSF) opened a 
purpose-built Ebola management centre (EMC) in Sierra 
Leone in Kailahun in June, 2014. The EMC initially 
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received patients from across the entire country and 
patients often endured long and debilitating journeys to 
reach the centre. In September, 2014, a second MSF EMC 
was opened in Bo, which is the second largest city in 
Sierra Leone and centrally located with good road access.
In this study, we report on children with Ebola virus 
disease admitted to the two EMCs in Kailahun and Bo. 
Given the paucity of clinical information on Ebola virus 
disease in young children and their vulnerability, we 
aimed to describe the clinical characteristics of children 
aged 5 years and under, report their signs and symptoms 
on arrival and during admission, and assess the factors 
associated with death.
Methods
Patients
We included all children aged 5 years and younger admitted 
to the Kailahun and Bo EMCs between June and December, 
2014, with conﬁ rmed Ebola virus disease. We used WHO 
case deﬁ nitions to screen people before testing.9 A 
suspected case was a person who had a sudden onset of 
fever and contact with a person with suspected, probable, 
or conﬁ rmed Ebola or a dead or sick animal. Or any person 
with sudden onset of high fever and at least three of the 
following symptoms: headache, lethargy, anorexia (loss of 
appetite), aching muscles or joints, stomach pain, diﬃ  culty 
swallowing, vomiting, diﬃ  culty breathing, diarrhoea, 
hiccups; or any person with inexplicable bleeding.
We used data that were collected for clinical purposes 
and anonymised before analysis. This study met the 
criteria of the MSF Ethics Review Board for exemption 
from ethics review for retrospective analyses of routinely 
collected programmatic data.10 The study protocol is 
available on the MSF open repository.
Procedures
Workers completed a case investigation form as soon as 
was feasible after the arrival of each patient and recorded 
demographic characteristics, exposure history, date of 
symptom onset, and past and present symptoms. Age 
was corroborated with family members whenever 
possible. After assessment of clinical status and 
epidemiological information, patients were admitted to 
“suspect/probable” tents and underwent a blood test, and 
people who tested positive for Ebola virus were 
transferred to a “conﬁ rmed” tent. Tests were done by 
laboratories run by the Public Health Agency of Canada 
(Kailahun) and the US Centers for Disease Control and 
Prevention (Bo).
Cases were conﬁ rmed by presence of Ebola virus RNA, 
detected with quantitative RT-PCR with two ampliﬁ cation 
targets in venous or capillary swab blood. The latter 
involved a capillary sample that was collected onto a 
cotton swab because venous sampling was not always 
feasible in young children. Results were accessible for 
83 patients as cycle thresholds (Ct), a measure inversely 
related to viral load. The translation of Ct into viral load 
was not identical between the two laboratories. We tested 
whole blood samples before discharge for patients who 
were clinically convalescing (that is, no vomiting or 
Panel: Research in context
Evidence before this study
We searched PubMed for articles relating to Ebola in children 
from Jan 1, 1976, to Aug 15, 2015. Search terms used were 
“paediatric” OR “pediatric” OR “child” AND “Ebola”. There is a 
paucity of clinical information on children with Ebola virus 
disease and we found no articles that described clinical features 
in young children during their inpatient stay. There are two 
relevant papers for Ebola virus disease in children. The ﬁ rst is a 
report by Mupere et al3 on 168 inpatients under 18 years of age 
aﬀ ected by Sudan Ebola virus in 2000–01 in Uganda. It includes 
only 20 patients with laboratory conﬁ rmed Ebola virus disease 
and does not disaggregate information by age. The second 
paper by the WHO Ebola Response Team presents the West 
African epidemic age-speciﬁ c outcomes and symptoms 
reported on arrival, but not during hospital admission. 
An important ﬁ nding in this paper was that children younger 
than 5 years have the highest case fatality.
Added value of this study
Our study focuses on the clinical features of Ebola virus disease 
in children aged 5 years and under. We describe, for 91 children, 
symptoms and outcomes conﬁ rmed by health-care workers 
during hospital admission in Ebola management centres. This 
study describes symptoms in relation to outcome and early 
symptoms. Signs signiﬁ cantly associated with death were fever, 
vomiting, diarrhoea, and distress. Hiccups, bleeding, and 
confusion were observed only in children who died. Our paper 
highlights the frequency (63·7%) of distress during admission. 
The case fatality in this cohort was 57·1% (52/91). Case fatality 
was highest in children under 2 years (76·5% [26/34)]) and in 
those with an Ebola virus cycle threshold <25 (81·8% [18/22]) 
indicating a higher viral load, compared with those patients 
with a cycle threshold ≥25 (45·9% [28/61]) at admission.
Implications of all available evidence
This study conﬁ rms the high rates of death in children younger 
than 2 years with Ebola virus disease, especially those with a 
high viral load at presentation. It gives insight into the 
symptom proﬁ le in younger children with Ebola virus disease 
and encourages the broader recognition of distress as a relevant 
symptom in this group, with implications for symptom relief in 
children and, possibly, for the improvement of training of 
clinical staﬀ  in distress and pain recognition and management. 
We highlight the dearth of knowledge on how Ebola virus 
disease aﬀ ects younger children. Programme managers and 
researchers should aim to collect and analyse age-speciﬁ c data 
so that the speciﬁ c vulnerabilities of young children are not 
overlooked. 
For the study protocol see 
http://fieldresearch.msf.org/msf/
handle/10144/583990
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diarrhoea and temperature <37·5°C for 3 consecutive 
days).11 During admission, empirical treatment followed 
standard protocols:11 this included initial treatment with 
antibiotics and antimalarial drugs as well as supportive 
treatment including hydration, pain relief, and 
nutritional support.
A standardised chart was used to record speciﬁ c 
symptoms and signs and axillary temperature was 
measured and recorded at least once daily. The same chart 
was used for children and adults. Clinical features assessed 
were: fever (temperature ≥38°C), hiccups, loss of appetite, 
vomiting, diarrhoea, breathlessness, cough, jaundice, skin 
rash, confusion, sore throat, conjunctival injection, 
haemorrhage, weakness, myalgia, arthralgia, abdominal 
pain, and headache. Clinical staﬀ  recorded data only if 
symptoms were observed; therefore, we assumed that 
missing data meant an absence of symptoms.
Data on temperature were summarised into one 
variable that captured whether a child had a temperature 
38°C or greater at any time on the day of observation. An 
undocumented temperature was considered a missing 
value. There were records of localised pain according to 
the symptom checklist. Pain as a symptom and its 
localisation are diﬃ  cult to determine accurately in 
children younger than 5 years, and there were no 
standardised objective tools to determine whether a 
child had pain. A single variable, “distress”, was applied 
when one or more of sore throat; headache; or 
abdominal, joint, or muscle pain was recorded. 
In a post-hoc analysis we summarised symptoms in a 
subgroup of children admitted within 3 days of reported 
symptom onset, to describe symptoms that occurred 
early in the course of illness but also with the advantage 
of limited recall bias as there was a shorter interval to 
recall symptoms because of their day of onset relative 
to admission.
We also analysed data with age grouped into <2 years 
or 2–5 years, since younger children are more vulnerable 
to infections. However, because the age–mortality 
relation is not linear, we selected an age cut-oﬀ  with 
clinical meaning: breastfeeding, a risk factor for high-
level exposure to the virus, generally ceases at age 2 years. 
Other variables included sex, EMC site, delay to 
admission to EMC from symptom onset (<1 week or 
≥1 week, reﬂ ecting early and late presenters, respectively, 
in this context), viral load of ﬁ rst positive test (based on 
previously published data, a Ct cutoﬀ  of 25 was used to 
indicate high viral load when Ct <25),12–14 and clinical 
features recorded during admission.
Two doctors reviewed the patient ﬁ les containing the 
case investigation form, daily symptom checklists, 
observations, and additional clinical notes.
Statistical analysis
We calculated the number and proportion of children 
experiencing the speciﬁ ed symptoms during admission 
and calculated exact CI for proportions using established 
methods.15 CIs were then presented, according to age 
and survival status, along with the overall case fatality 
by age.
We used χ² tests to assess unadjusted associations 
between demographic characteristics, laboratory results, 
occurrence of symptoms, and the probability of death 
while admitted to an EMC. We then assessed the 
association between death and potential risk factors 
using a left-truncated Cox regression model in which 
patients with a known date of disease onset contributed 
to the population at risk from the time they were admitted 
to an EMC. The adjusted model included all available 
variables considered, a priori, as potentially associated 
with death: age, sex, EMC site, and viral load. We used 
unadjusted Kaplan-Meier curves and the log rank test to 
compare survival patterns by age group and viral load. 
Data cleaning and analysis were done with Stata versions 
11.2 and 14.1 (StataCorp, College Station, TX, USA).
<2 years
(n=34)
2–5 years
(n=57)
Death 26 (76·5%) 26 (45·6%)
Weakness 21 (61·8%) 47 (82·4%)
Fever† 27 (79·4%) 36 (63·2%)
Distress‡ 11 (32·4%) 47 ( 82·5%)
Loss of appetite 15 (44·1%) 40 (70·2%)
Diarrhoea 24 (70·6%) 30 (52·6%)
Cough 17 (50·0%) 31 (54·4%)
Vomiting 13 (38·2%) 24 (42·1%)
Data are n (%). *Common symptom=symptom documented >35 times. 
†Two patients were excluded from this analysis because they did not have one or 
more temperature recordings during admission. ‡ Includes reports of headache, 
myalgia, arthralgia, abdominal pain, or sore throat. 
Table 1: Case fatality and common symptoms and signs during 
admission by age group*
Number 
of cases
Number of 
deaths (%)
Unadjusted analysis* Adjusted analysis*
HR (95% CI)* p HR (95% CI)* p
Age (years)
<2 34 26 (76·5%) 1·9 (0·9–3·9) 0·09 3·5 (1·5–8·5) 0·0047
2–5 57 26 (45·6%) 1·0 1·0
Sex
Male 48 26 (54·2%) 0·9 (0·4–1·8) 0·72 1·0 (0·5–2·1) 0·95
Female 43 26 (60·5%) 1·0 1·0
EMC location
Kailahun 57 32 (56·1%) 0·7 (0·3–1·4) 0·35 1·2 (0·5–2·7) 0·74
Bo 34 20 (58·8%) 1·0 1·0
Ebola viral load†
Ct<25 22 18 (81·8%) 5·5 (2·7–11·3) <0·0001 9·2 (3·8–22·5) <0·0001
Ct≥25 61 28 (45·9%) 1·0 1·0
EMC=Ebola management centre. Ct=cycle threshold. *HR includes only those patients with a known date of disease 
onset. †Includes only those 61 patients with a known date of disease onset and with a Ct result recorded at admission.
Table 2: Final regression model of variables associated with death
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Role of the funding source
There was no funding source for this study. TS had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Between June 26 and Dec 31, 2014, 1686 patients were 
cared for at the EMCs in Bo and Kailahun. Of the 
1269 patients with conﬁ rmed Ebola virus disease, 
97 (7·6%) were aged 5 years or younger (62/857 [7·2%] 
in Kailahun and 35/412 [8·5%] in Bo); data were 
missing for six children and, thus, 91 children were 
included in our cohort. Median age was 3 years 
(IQR 1–4) and 43 (47%) were girls; 52 (57·1%) children 
died.
The identity of the source case was not recorded for 
37 (41%) children. The source case was a non-parent 
relative for 22 children (24%) and a parent in 35% (32) of 
children; the proportion of parent source-cases was 
47% (16/34) in children younger than 2 years and 
28% (16/57) in the 2–5 years age group.
For the 67 (74%) children for whom the date of 
symptom onset was recorded, the median delay to 
admission was 4 days (IQR 2–7 days). Median length of 
stay for all admitted children was 8 days (IQR 5–13 days).
Ct and date-of-onset data were available for 61 children, 
and we did adjusted analysis on data from this subset of 
children. In an adjusted model including all variables 
considered, a priori, of interest, age and Ct result were 
signiﬁ cantly associated with case fatality, but sex and 
EMC site were not. Case fatality was higher in children 
younger than 2 years (76·5% [26/34]) than in those aged 
2–5 years (45·6% [26/57]) (table 1; data by 1-year age 
groups shown in the appendix p 1), adjusted HR 3·5 
(95% CI 1·5–8·5; table 2, ﬁ gure 1. Those with Ct <25 
were nine times as likely to die as those who had a Ct ≥25 
(81·8% [18/22] vs 45·9% [28/61], respectively; adjusted 
HR 9·2 [95% CI 3·8–22·5]; ﬁ gure 2, table 2). The 
proportional hazards assumption was marginally violated 
for the age variable. However, in a secondary adjusted 
analysis stratiﬁ ed by age there was little change in 
adjusted HRs.
Of symptoms reported during admission, hiccups, 
bleeding, and confusion were present only in children 
who died (7·7%, 26·9%, 11·5%, respectively; table 3, 
ﬁ gure 3). Three symptoms, on unadjusted analysis, were 
signiﬁ cantly more common in those who died than those 
who survived: fever (80·0 vs 59·0%; p=0·030), vomiting 
(51·9 vs 25·6%; p=0·012), and diarrhoea (75·0 vs 38·5%; 
p<0·001; table 3). Conversely, distress was more 
commonly reported for children who survived compared 
with those who died (82·1 vs 50·0%; p=0·002), where the 
proportion of all children with distress documented 
during admission was 63·7% (95% CI 53·0–73·6; 
table 3).
Weakness, fever, distress, loss of appetite, diarrhoea, 
and cough were present in more than half the children at 
some point during admission (table 3). Data on fever 
were recorded for 76 children (84%); of these, 19 (25%) 
had no fever either reported in their history before 
admission or a measured temperature <38°C on the day 
of admission. Therefore, they did not meet the WHO 
deﬁ nition for a suspected case. In a subgroup of 
27 children who presented within 3 days of illness onset, 
weakness (76·2%), fever (70·8%), loss of appetite 
(52·6%), and diarrhoea (50·0%) were commonly 
reported at admission (ie, these symptoms occurred on 
days 1–3 of illness), but only fever (56·5%) and weakness 
(40·7%) were frequent in the 3 days after admission 
(appendix p 2).
Discussion
We have presented an overview of Ebola virus disease in 
young children that includes data on symptoms during 
admission. All children with hiccups, bleeding, or 
confusion died. Furthermore, unadjusted analysis 
Figure 2: Unadjusted Kaplan-Meier survival estimates by viral cycle threshold
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showed a signiﬁ cant association between a fatal outcome 
and symptoms of vomiting, diarrhoea, and fever during 
admission. Weakness, fever, and distress were present in 
more than 63% of the children, and more than half had 
loss of appetite, diarrhoea, and cough. At admission, 25% 
of children did not have fever. Case fatality was 57·1% 
overall and was higher in children younger than 2 years 
than in those aged 2–5 years and in those with a high 
viral load.
The paucity of published age-disaggregated symptom 
data in young children during admission for Ebola virus 
disease hinders comparison of our results. In Uganda, 
in 2000–01, Mupere and colleagues3 reported data for 
168 inpatients younger than 18 years aﬀ ected by Sudan 
Ebola virus. However, they included only 20 patients 
with laboratory-conﬁ rmed disease and did not 
disaggregate clinical observations by age. In 2015, the 
WHO Ebola Response Team in west Africa reported 
age-speciﬁ c outcomes for Guinea, Liberia, and Sierra 
Leone.2 However, as with other published descriptions 
of the epidemic, the authors reported only symptom 
history on arrival at health facilities.2,6,8 In our experience 
it was often diﬃ  cult to elicit a reliable symptom history 
on arrival at the EMC. The symptom proﬁ le of children 
once admitted diﬀ ered from the history of symptoms 
reported at admission, with some indication of this 
eﬀ ect even in children who presented in the ﬁ rst 3 days 
of their illness. This diﬀ erence might reﬂ ect disease 
evolution, but could also be a discrepancy between 
reported and actual symptoms.
The presence of weakness, fever, and distress in most 
of the children in our cohort is similar to the ﬁ ndings of 
Qin and colleagues16 who reported these signs and 
symptoms in more than half of their all-age cohort 
during admission. Some symptoms (gastrointestinal 
symptoms, fever, disorientation, hiccups, and bleeding) 
were more prevalent in patients who died. Qin also noted 
an association between vomiting, diarrhoea, loss of 
appetite, weakness, and “mental symptoms” and death.16 
All children with confusion, bleeding, and hiccups in our 
cohort died, suggesting that these symptoms could be 
strongly associated with a fatal outcome.
Pain has consistently been reported less often in 
children with Ebola virus disease than in adults,2 possibly 
because of the diﬃ  culty in identifying pain in children. 
We acknowledge that pain is a subjective and diﬃ  cult 
symptom to deﬁ ne, and that a caregiver report is not 
entirely reliable indicator of pain. Since objective tools to 
classify pain in young children were not used in our 
cohort, we classiﬁ ed any symptom suggestive of pain 
(sore throat, myalgia, arthralgia, abdominal pain, or 
headache) as distress. Distress was reported less 
frequently in children who died. This ﬁ nding might be a 
pathophysiological reality, represent good palliative care, 
or perhaps reﬂ ect poorer recognition of distress in 
children who were too sick to visibly show discomfort. 
Distress was also reported less commonly in children 
younger than 1 year, probably the result of poorer 
identiﬁ cation of pain in this youngest age group. In 
summary, a substantial proportion of children with Ebola 
virus disease experience distress, to which pain could be 
an important contributor. Eﬀ orts to objectively quantify 
pain, especially in the pre-verbal child, would be an 
important addition to clinical care protocols.
The WHO case deﬁ nition for suspected Ebola virus 
disease, requiring fever, has been shown to be insensitive 
across all ages and our data support this ﬁ nding for 
Patients who 
survived (n=39)
Patients who 
died
(n=52)
p (survived vs 
died)
All patients 
(n=91)
Fever (reported or ≥38°C) 23 (59·0%) 40* (80·0%) 0·0304 63* (70·8%)
Hiccups 0 4 (7·7%) 0·07 4 (4·4%)
Loss of appetite 25 (64·1%) 30 (57·7%) 0·5 55 (60·4%)
Vomiting 10 (25·6%) 27 (51·9%) 0·0115 37 (40·7%)
Diarrhoea 15 (38·5%) 39 (75·0%) 0·0004 54 ( 59·3%)
Breathlessness 3 (7·7%) 12 (23·1%) 0·0503 15 (16·5%)
Cough 22 (56·4%) 26 (50·0%) 0·54 48 (52·7%);
Jaundice 0 0·0% 0
Skin rash 3 (7·7%) 3 (5·8%) 0·71 6 (6·6%)
Confused/ disoriented 0 6 (11·5%) 0·0282 6 (6·6%)
Conjunctival injection 7 (17·9%) 5 (9·6%) 0·24 12 (13·2%)
Bleeding 0 14 (26·9%) 0·0004 14 (15·4%)
Weakness 29 (74·4%) 39 (75·0%) 0·94 68 (74·7%)
Distress† 32 (82·1%) 26 (50·0%) 0·0016 58 (63·7%)
Data are n (%), unless otherwise stated. *Two patients did not have at least one recorded temperature during 
admission so were not included: N=50 for patients who died; N=89 for all patients for fever.†Any of headache, 
myalgia, arthralgia, abdominal pain, or sore throat reported. 
Table 3: Symptom prevalence during admission by outcome
Figure 3: Outcome according to symptom and sign prevalence during overall admission period
*Any of headache, myalgia, arthralgia, abdominal pain, or sore throat reported. †Two patients did not have at least 
one recorded temperature during admission so were not included.
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children aged 5 years and younger.17 In our cohort, the 
requirement of fever would miss 25% of cases at initial 
presentation, which is an unacceptably high proportion 
of patients.
The 76·5% case fatality we observed in children younger 
than 2 years was higher than that in older children in the 
cohort, and higher than older patients admitted to the 
same EMCs (case fatality rate 42% in conﬁ rmed cases 
aged older than 5 years; unpublished programme data, 
JG personal communication). This ﬁ nding concurs with 
data published elsewhere,2 and suggests a heightened 
physiological and sociological vulnerability of infants, 
especially where a related caregiver was not always 
present or able to provide care. Unfortunately, there was 
insuﬃ  cient information available from our cohort to 
explore the role of a reduced level of care or complete 
absence of a known caregiver on mortality. Our ﬁ nding 
that children with a high viral load at admission were 
nine times more likely to die than those with a low viral 
load is consistent with the association of viral load and 
case fatality noted across all ages in the west Africa 
outbreak.12,18 The longer delay to arrival in those who 
survived compared with those who died most likely 
reﬂ ects survivor bias; children who had a milder illness 
were more likely to survive to reach the EMC.
A strength of our analysis is that it includes ongoing 
inpatient signs and symptoms, allowing for their 
evolution over time. These signs and symptoms were 
veriﬁ ed by clinical staﬀ , and we did not rely on self-report 
or caregiver report. However, an inherent limitation of 
our retrospective analysis is that data were collected for 
programmatic purposes under diﬃ  cult ﬁ eld conditions, 
with few trained staﬀ . This constraint is reﬂ ected through 
missing records and variables, including epidemiological, 
symptom, and treatment information. Missing data on 
the clinical checklist were assumed to mean the symptom 
was absent; however, it might also be the result of staﬀ  
not comprehensively documenting the symptom proﬁ le. 
The reliability of some variables such as the date of 
symptom onset and age may have been aﬀ ected by 
problems of recall, as well as by children arriving 
unaccompanied or with unfamiliar caregivers. The 
absolute numbers of children with discrete symptoms 
and signs were small; however, we did identify signiﬁ cant 
associations between individual symptoms and mortality.
An important limitation of the study relates to the 
Ct measurement, as there was probably variation between 
the two laboratories in the translation of Ct into an 
objective measure of viral load. We used a cut-oﬀ  of Ct 25 
for high and low viral load. The interpretation across 
diﬀ erent laboratory providers of Ct in relation to replication 
competent viral load urgently requires harmonisation 
given the importance of this parameter. However, inclusion 
of site of testing in the model did not aﬀ ect the outcome, 
lending support to our approach to combine data from the 
two laboratories for analysis. Finally, our study included 
only children admitted to EMCs, and thus is not necessarily 
applicable to overall Ebola-related morbidity and mortality 
in paediatric cases in the community.
Our ﬁ ndings support existing data that show that 
young children with Ebola virus disease have a very high 
case fatality rate. Children with a high viral load at 
presentation are especially vulnerable. Programme 
managers and researchers should aim to collect and 
analyse age-speciﬁ c data so that the speciﬁ c vulnerabilities 
of children are not overlooked.
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